<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Myriad Pharmaceuticals Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/myriad-pharmaceuticals-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(MYGN) Myriad Reports Strong Earnings of 37 Cents vs. 23 Cents Estimate</title>
		<link>http://www.stockbloghub.com/2009/08/26/mygn-myriad-reports-strong-earnings-of-37-cents-vs-23-cents-estimate/13446</link>
		<comments>http://www.stockbloghub.com/2009/08/26/mygn-myriad-reports-strong-earnings-of-37-cents-vs-23-cents-estimate/13446#comments</comments>
		<pubDate>Wed, 26 Aug 2009 16:09:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[Myriad Pharmaceuticals Inc]]></category>
		<category><![CDATA[MYRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13446</guid>
		<description><![CDATA[Yesterday, Myriad Genetics Inc. (MYGN) reported fourth quarter earnings of 37 cents per share from continuing operations. This was well above the Zacks Consensus Estimate of 23 cents. For fiscal year 2009, the company earned $1.38 per share from continuing operations. Molecular Diagnostic Revenues for the quarter came in at $86.1 million, versus $64.7 million for the same period of the prior year, thus reflecting a 33% increase. Fiscal 2009 saw a 47% increase in revenues to $326.5 million from $222.9 million in the year-ago period. The improvement was attributable mainly to Myriad&#8217;s increased sales and marketing efforts, which have created higher demand for the company&#8217;s molecular diagnostic products. However, revenue growth slowed down during the second half due to the recession. Myriad has undertaken several measures Incorporatedluding adding 50 new ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/26/mygn-myriad-reports-strong-earnings-of-37-cents-vs-23-cents-estimate/13446/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

